Arvinas to Present at Upcoming Investor Conferences
02 Mai 2024 - 1:00PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
two upcoming investor conferences:
- BofA Securities 2024 Healthcare Conference on Tuesday,
May 14 at 3:00 p.m. PT in Las Vegas.
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy
Teel, Ph.D., Chief Business Officer, will participate in a fireside
chat. A live audio webcast of the presentation will be available
here and on the Events and Presentations section of the Company’s
website.
- UBS Spring Biotech Conferences on Tuesday, May
21.
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy
Teel, Ph.D., Chief Business Officer, will participate in investor
1x1 meetings.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has four investigational clinical-stage programs:
vepdegestrant (ARV-471) for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer; ARV-766 and
bavdegalutamide for the treatment of men with metastatic
castration-resistant prostate cancer; and ARV-102 for the treatment
of patients with neurodegenerative disorders. For more information,
visit www.arvinas.com.
Contacts Investors:Jeff
Boyle+1 (347) 247-5089Jeff.Boyle@arvinas.com
Media:Kathleen Murphy+1 (760)
622-3771Kathleen.Murphy@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024